RNXT files 8-K with Q3 FY2025 results press release attached

Rhea-AI Filing Summary

RenovoRx (RNXT) furnished an update via an 8-K stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The company also included updates on its clinical trial and commercialization strategy as described in the press release.

The press release is attached as Exhibit 99.1 and incorporated by reference. RNXT’s common stock trades on the Nasdaq Capital Market under the symbol RNXT.

8-K Event Classification

3 items: 2.02, 8.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001574094 0001574094 2025-11-13 2025-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2025

RENOVORX, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40738		27-1448452
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2570 W El Camino Real, Suite 320 Mountain View, CA				94040
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (650) 284-4433

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		RNXT		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 13, 2025, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial results as of and for the quarter ended September 30, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 8.01 Other Events.

In addition to announcing certain financial results, the Company’s press release provides certain updates of the Company’s clinical trial and commercialization strategy described in such press release. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release of RenovoRx, Inc., dated November 13, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		RENOVORX, INC.
Date:	November 13, 2025
		By:	/s/ Shaun R. Bagai
		Name:	Shaun R. Bagai
		Title:	Chief Executive Officer

-3-

FAQ

What did RNXT announce in its 8-K?

RenovoRx announced it issued a press release with financial results for the quarter ended September 30, 2025, and provided clinical and commercialization updates.

Which period do the results cover for RNXT (RNXT)?

The results cover the quarter ended September 30, 2025.

How did RenovoRx provide the detailed results and updates?

Details are provided in a press release attached as Exhibit 99.1 and incorporated by reference.

Where can investors find RNXT’s press release?

The press release is included as Exhibit 99.1 to the 8-K.

Did RNXT include clinical trial or commercialization updates?

Yes. The press release includes updates on the company’s clinical trial and commercialization strategy.

What is RenovoRx’s trading symbol and exchange?

RenovoRx trades on the Nasdaq Capital Market under the symbol RNXT.

What exhibits are listed in the 8-K?

Exhibit 99.1 (press release) and Exhibit 104 (cover page Inline XBRL data file).